Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay

Br J Haematol. 2007 Oct;139(1):159-61. doi: 10.1111/j.1365-2141.2007.06753.x.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antigens, Human Platelet / immunology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • HLA Antigens / immunology*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Isoantibodies / analysis*
  • Leukemia, Myeloid / immunology*
  • Leukemia, Myeloid / therapy*
  • Middle Aged
  • Platelet Transfusion*
  • Transplantation, Homologous
  • Treatment Failure

Substances

  • 5a alloantigen, human
  • Antigens, Human Platelet
  • HLA Antigens
  • Isoantibodies